Every material Form 8-K CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. has filed with the SEC since November 12, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Creative Medical Technology Holdings (CELZ) agreed on September 24, 2026 to buy 4,000,000 BioDefense common shares from Creative Acquisition Corp. (CAC), a company controlled by CEO Timothy Warbington. The company paid $200,000 in cash and 1,000,000 of its own common shares, raising its stake in BioDefense to 80%, which is a related-party transaction shareholders should weigh.
Purchase of 4,000,000 BioDefense shares from CAC for $200,000 in cash plus 1,000,000 CELZ common shares
After the deal, CELZ owns 16,000,000 BioDefense shares (80%) and CAC owns 4,000,000 (20%)
CEO Timothy Warbington is Chairman and CEO of CAC and indirectly owns all of its shares
The 1,000,000 CELZ shares were issued to CAC in a private placement under Section 4(a)(2) of the Securities Act
On June 30, 2026, Creative Medical Technology Holdings agreed with warrant holders to exercise existing warrants for 2,790,340 shares at a reduced price of $1.60 per share, down from $2.86, for gross proceeds of about $4.5 million before advisory fees. In exchange, the company issued new warrants for 5,580,680 shares at $1.60, which cannot be exercised until stockholder approval is obtained, so the transaction adds both cash and potential future share issuance for shareholders.
Existing warrants for 2,790,340 shares were exercised at $1.60 per share, reduced from $2.86, for about $4.5 million in gross proceeds before advisory fees.
New Inducement Warrants cover 5,580,680 shares at $1.60 and are exercisable for five years after Nasdaq-required stockholder approval.
Roth Capital Partners, LLC receives a fee of 8% of gross proceeds plus $50,000 in reimbursed legal expenses.
On July 1, 2026, the Compensation Committee approved a $100,000 bonus for CEO Timothy Warbington.
Creative Medical Technology Holdings' Compensation Committee approved bonuses of $100,000 for CEO Timothy Warbington and $25,000 for CFO Donald Dickerson on November 6, 2025, according to an 8-K filed November 12, 2025. The filing does not state the basis for the bonuses or any performance criteria, and it contains no financial results or changes in officer roles.
Compensation Committee approved the bonuses on November 6, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →